UH has announced a new multi-disciplinary institute to promote drug discovery. Photo courtesy of UH

The University of Houston has introduced a new institute to its campus. The multi-disciplinary program includes both on-campus and citywide collaboration.

UH has established the Drug Discovery Institute in order to streamline and modernize drug discovery. In partnership with the Texas Medical Center, as well as other organizations, the DDI will tap into technology and innovation to advance modern medicine. The institute will collaborate with the UH colleges of Pharmacy, Natural Sciences and Mathematics and Cullen College of Engineering.

"Our new Drug Discovery Institute could not have been launched at a more appropriate juncture. With the frantic quest for effective drugs to counter the current and future viral infections, the broad and deep strength of the University of Houston is being brought to bear and will no doubt advance the development of innovative cures," says Amr Elnashai, vice president for research and technology transfer, in a press release.

The university currently has about 100 faculty members conducting drug discovery-related research, but, according to the release, these efforts have been fragmented. With DDI, UH hopes to bring these efforts together under one roof in order to promote synergistic research.

F. Lamar Pritchard, dean of the UH College of Pharmacy, has been advocating for the idea of a collaborative drug discovery research center for more than a decade

"The breadth of this initiative will establish the institute and the University among the national leaders in drug discovery and become one of the first to fully embrace AI into its academic drug discovery programs," Pritchard says in the release.

The new institute will be led by Ruiwen Zhang, Robert L. Boblitt Endowed Professor in Drug Discovery at the College of Pharmacy,. He will hold the position of director for two years, before the title rotates through the collaboration of colleges.

"Working together is critical, none of us can do this alone," Zhang says in the release. "In drug discovery, a chemist needs a biologist, a biologist needs a pharmacologist, and so on. We will build a platform and infrastructure, along with the necessary tools, to bring everyone together."

The facility will work to promote each of the school's expertise across many aspects of the drug discovery process — including high-throughput screening technologies, organ-on-chip models, biosensing and biofeedback, molecular modeling and more.

"Practicing team science is key to making innovative discoveries and we are eager to collaborate with faculty across the University to develop cutting-edge research and ultimately to find treatments and cures for disease," says Dan Wells, dean of the College of Natural Sciences and Mathematics, in the release.

Additionally, DDI will offer seed grants for interdependent drug-discovery projects and encourage collaboration and the sharing of data with experts around the world

"I foresee one day in the near future that we are able to create some of the strongest databases and artificial intelligence approaches to drug discovery," Pritchard says in the release. "Rather than having to screen millions of compounds to find one therapy, we may be able to narrow that down to 1,000 and really streamline the process."

UH has been ranked among the top schools for new patents. Photo courtesy of University of Houston

University of Houston scores spot on top schools in the world for new patents

put a patent on it

A Houston school has ranked on a global list that recognizes new utility patents issued. University of Houston tied for No. 75 on the list with 39 utility patents issued in 2019.

The list is created by the National Academy of Inventors and the Intellectual Property Owners Association based on data from the U.S. Patent and Trademark Office. UH has made the list every year for the past five years.

"The rankings show that UH continues to make a major contribution to the innovation enterprise on the U.S. and global stage," says Amr Elnashai, vice president/vice chancellor for research and technology transfer at UH.

"To be in the top 100 universities worldwide for U.S. patents emphasizes that the UH research enterprise has been successfully steered towards impactful research with the potential to address societal challenges."

A utility patent, known as a patent for invention, is the most commonly referred to type of patent and regards the creation of a new or improved product, process, or machine.

Two Texas schools ranked above UH on this year's list. The University of Texas ranked at No. 3 with 276 utility patents and Texas A&M University came in a few spots ahead of UH at No. 65 with 44 utility patents issued.

UH tied with Drexel University in Philadelphia, and the University of California scored the top spot by far with 631 utility patents filed last year. All in all, the ranking finds that 7,873 U.S. utility patents were issued in 2019, which is up from 1,046 patents in 2018.

UH's Technology Bridge was revamped in 2018 to focus on cultivating innovation and new technologies as they develop from the lab and into the marketplace.

There's a growing need for physician-scientists who can see from both sides of the table. Miguel Tovar/University of Houston

University of Houston researchers on why bridging the gap between academia and clinicians is key

Beaker to bedside

Physician-scientists are a group of specialized researchers at the intersection of medicine and technology. Earning both medical degrees and Ph.D.s, they offer a perspective beyond the scope of clinical practice.

Three such researchers discussed how they make the connections between discovery and patient care.

Why a dual education matters

Shaun Xiaoliu Zhang, director of the Center for Nuclear Receptors and Cell Signaling at the University of Houston and M.D. Anderson professor of biology and biochemistry, knows exactly what the clinical demands are.

"I can see from the M.D. perspective, but at the same time I have a Ph.D. — I know how to design research properly," he says. "In the clinic, you're faced with reality that a patient is struggling but you don't have the tools to treat those patients. If you engage in research you can create a tool."

Zhang says clinicians know the need but may struggle to design a solution. A Ph.D., on the other hand, may only know basic research.

Renowned hormone researcher Jan-Åke Gustafsson, Robert A. Welch professor of biology and biochemistry and founding director of the Center for Nuclear Receptors and Cell Signaling, agrees.

"The dual education makes it possible for you to see which diseases are in need of more research, drugs and so on," he says.

Physician-scientists are the driving force behind many advances of modern medicine.

"The way I look at it is, practicing medicine is relatively easy but coming up with the next diagnostic device or the next treatment for a disease is way more difficult, way more challenging," says Chandra Mohan, Hugh Roy and Lillie Cranz Cullen Endowed professor of biomedical engineering at UH.

"You see patients with certain diseases, and you know there's a dire need for better diagnostics, earlier treatment, earlier diagnosis with fewer side effects," he says.

While researchers spend time primarily in the laboratory and clinical practitioners interact with patients, they both want to make an impact.

"We have made some discoveries which have led to the development of new drugs and better understanding of certain diseases," says Gustafsson. "There's a great satisfaction that it may help people to get healthy."

Traditional research brings value to a university

The synergy of this dual education makes these investigators valuable not only to academia, but also to medical science.

"I can't imagine doing translational research without medical training," Zhang says. "If you have this part without the other, you don't know where to go. With medical training, you know exactly which direction to go."

Mohan echos that assessment.

"When you start doing research there are so many questions you can answer," he says. "Sometimes there are questions which are just too basic. They're too far removed from how it will impact a patient's life. So what are the most important questions? I think questions that really make a difference in the patient's life are the most important."

Zhang notes that the National Institutes of Health has switched its funding philosophy — once focused on basic science, it now is more interested in translational research, with a direct relationship to patient health.

As physician-scientists, these "translators" of medical research are able to bridge the chasm.

Amr Elnashai, vice president/vice chancellor of research and technology transfer at UH, says physician-scientists play an important role.

"The increasing importance of deploying technology in medicine renders it essential for a progressive research university to hire medical Ph.D. holders who are in an ideal position to bridge the gap between engineering and science on the one hand, and the broad field of medicine on the other," he says.

Research groups that bring both fields together not only have a much higher probability of impacting lives by adopting the latest technology in medical applications, he adds, but they also give interdisciplinary teams greater access to specific funding pursue such solutions.

In that sense, says Elnashai, medical Ph.D. researchers play an important part of the future research university.

------

This article originally appeared on the University of Houston's The Big Idea.

Nitiya Spearman is the internal communications coordinator for the UH Division of Research.

UH has maintained its spot on the top 100 global universities for number of patents issued. Photo courtesy of University of Houston

University of Houston ranks among top schools for issued patents

best in class

A new ranking shows the University of Houston is flexing its brains and its brawn as one of the most prolific producers of patents in the academic world.

The new ranking, published by the National Academy of Inventors and the Intellectual Property Owners Association, puts UH at No. 88 among the world's top 100 universities for patent activity in 2018.

"As the UH research portfolio grows and the medical school starts up, we would continue to anticipate a strong IP portfolio going forward for UH," says Tom Campbell, executive director of the Office of Technology Transfer and Innovation at UH.

UH tied with the Texas A&M University on this year's list; each recorded 28 patents in 2018. A year earlier, UH received 39 patents. The University of Texas was the only other Texas school on the new list. With 187 patents issued in 2018, it landed at No. 5.

Houston's Rice University showed up at No. 79 on the 2018 list but dropped out of this year's top 100.

Amr Elnashai, UH's vice president and vice chancellor for research and technology transfer since 2017, says his school's appearance in the ranking reflects an emphasis on converting faculty inventions into meaningful innovations. During the 2018 budget year, UH collected $43 million in patent royalties.

Among the patents UH received last year were those for a mutant herpes simplex virus connected to cancer therapy and a rechargeable alkaline battery.

"UH researchers are driven by making a positive impact on the quality of life," Elnashai says in a release. "From new remedies for persistent medical conditions to sustainable energy technologies, researchers from the University of Houston are addressing many of the world's most pressing challenges. The UH ranking, tied with our larger neighbor Texas A&M, is a testament to our emphasis on and excellence in technology transfer and innovation."

To ramp up UH's impact, the university last year rebranded its research park as the UH Technology Bridge. With 30,000 square feet of incubator space and over 700,000 square feet of space for labs, pilot-scale facilities, and light manufacturing, the Technology Bridge houses 21 startups and two established companies.

"From clean energy solutions and medicines to uses of artificial intelligence, data science tools and other emerging technologies, the University of Houston is focusing on bridging the gap between technological discoveries by our faculty and actual products that change peoples' lives," Elnashai said in 2018.

The list from the National Academy of Inventors and the Intellectual Property Owners Association started in 2013. UH first cracked the top 100 in 2016 (for patents issued in 2015). That year, it ranked 88th. UH dropped to No. 91 on the 2017 list but rose to No. 67 on the 2018 list.

"The patents our universities produce represent important processes and collaborations which have the potential to make a significant impact on society on a local, regional, national, and global scale," says Paul Sanberg, president of the National Academy of Inventors.

The annual ranking relies on data from the U.S. Patent and Trademark Office regarding utility patents, which make up 90 percent of all patents issued.

According to Investopedia, a utility patent covers the creation of a new or improved — and useful — product, process, or machine. This type of patent prohibits other people or companies from making, using, or selling the invention without authorization.

"Patenting an invention is the first step towards making a lasting impact on the innovation ecosystem," says Jessica Landacre, deputy executive director of the Intellectual Property Owners Association.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston investor on why 2025 will be the year of exits

houston innovators podcast episode 270

Samantha Lewis will be the first to admit that the past few years have been tough on startups and venture capital investors alike. However, as she explains on the Houston Innovators Podcast, the new year is expected to look very different.

"We're super excited going into 2025," says Lewis, who is a partner at Houston-based VC firm Mercury. "For us, 2024 was a year of laying a lot of groundwork for what we believe is going to be a massive year of startup exits and liquidity for the venture ecosystem. We've been hard at work making sure our companies are prepared for that."

Mercury, in fact, has already gotten a taste, with three of its portfolio companies celebrating exits — all with Houston roots. Fintech platform Brassica was acquired by BitGo in February, and Apparatus, founded as Topl in Houston, was acquired early last year. The third deal has yet to be announced publicly.

And it's just getting started, Lewis says. She explains that all of the companies in Mercury's portfolio that are promising — albeit not break-out, to-be-billion-dollar companies — are going to have opportunities to sell in 2025 and 2026.

"What we've started to do — and I encourage everyone to do this if you're working on a startup — is just start to just engage with strategic buyers, investment bankers, and people you think might be a great fit to buy your company," Lewis says, "because we really think that the next few years will be the best liquidity years we've seen in a really long time. And if you're not ready for it, you're going to miss the boat."

In addition to sharing her advice to get "exit preparedness," Lewis explains some specific tech trends she's keeping an eye on in Mercury's "power theme," which she works on directly. This encompasses fintech, blockchain, web3 and more.

SpaceX loses mega rocket in latest thrilling Starship test flight

Testing

SpaceX launched its Starship rocket on its latest test flight Thursday, but the spacecraft was destroyed following a thrilling booster catch back at the pad.

Elon Musk’s company said Starship broke apart — what it called a “rapid unscheduled disassembly." The spacecraft's six engines appeared to shut down one by one during ascent, with contact lost just 8 1/2 minutes into the flight.

The spacecraft — a new and upgraded model making its debut — was supposed to soar across the Gulf of Mexico from Texas on a near loop around the world similar to previous test flights. SpaceX had packed it with 10 dummy satellites for practice at releasing them.

A minute before the loss, SpaceX used the launch tower's giant mechanical arms to catch the returning booster, a feat achieved only once before. The descending booster hovered over the launch pad before being gripped by the pair of arms dubbed chopsticks.

The thrill of the catch quickly turned into disappointment for not only the company, but the crowds gathered along the southern tip of Texas.

“It was great to see a booster come down, but we are obviously bummed out about [the] ship,” said SpaceX spokesman Dan Huot. “It’s a flight test. It’s an experimental vehicle," he stressed.

The last data received from the spacecraft indicated an altitude of 90 miles and a velocity of 13,245 mph.

Musk said a preliminary analysis suggests leaking fuel may have built up pressure in a cavity above the engine firewall. Fire suppression will be added to the area, with increased venting and double-checking for leaks, he said via X.

The 400-foot rocket had thundered away in late afternoon from Boca Chica Beach near the Mexican border. The late hour ensured a daylight entry halfway around the world in the Indian Ocean. But the shiny retro-looking spacecraft never got nearly that far.

SpaceX had made improvements to the spacecraft for the latest demo and added a fleet of satellite mockups. The test satellites were the same size as SpaceX’s Starlink internet satellites and, like the spacecraft, were meant to be destroyed upon entry.

Musk plans to launch actual Starlinks on Starships before moving on to other satellites and, eventually, crews.

It was the seventh test flight for the world’s biggest and most powerful rocket. NASA has reserved a pair of Starships to land astronauts on the moon later this decade. Musk’s goal is Mars.

Hours earlier in Florida, another billionaire’s rocket company — Jeff Bezos’ Blue Origin — launched the newest supersized rocket, New Glenn. The rocket reached orbit on its first flight, successfully placing an experimental satellite thousands of miles above Earth. But the first-stage booster was destroyed, missing its targeted landing on a floating platform in the Atlantic.

Houston private equity firm beats target on first investment fund

fresh funds

Houston-based private equity firm Sallyport has raised $160 million for its first investment fund, exceeding the target amount by $10 million.

The Sallyport Partners Fund focuses primarily on investments in founder- and family-owned businesses, corporate carve-outs and startups in various industries.

The firm’s chairman, Doug Foshee, seeded the fund. He and managing partners Kyle Bethancourt and Ryan Howard started the firm in 2023.

“Sallyport Partners Fund was created to utilize the proven processes our team has developed over time to generate value for like-minded investors on a larger and more impactful scale,” Foshee says in a news release.

Investors in the Sallyport fund include entrepreneurs, business executives and influential Texas families. Aside from Foshee, names of the fund’s investors weren’t disclosed.

“We are deeply committed to working hand-in-hand with management teams to drive transformative growth and generate long-term value,” says Bethancourt. “Our operational capabilities are forged from decades of firsthand experience leading, investing in, and building thriving businesses from the ground up. We have a unique appreciation for the management team’s perspective because we’ve been in their shoes.”

Those shoes have covered some pretty impressive ground:

  • Foshee is former chairman, president, and CEO of Houston-based El Paso Corp., which owned and operated a 44,000-mile natural gas pipeline network. In 2012, El Paso merged with Houston-based pipeline company Kinder Morgan in a multibillion-dollar deal.
  • Before Sallyport, Bethancourt was a vice president in the credit division of Blackstone, an investment powerhouse with more than $1 trillion in assets under management. Earlier, he worked at D.E. Shaw & Co., a New York City-based hedge fund with more than $65 billion in assets under management.
  • Before Sallyport, Howard worked at Platform Partners, a Houston-based private equity firm. Earlier, he worked for the natural resources arm of investment banking giant Goldman Sachs.